Clinical trial / 2010
Milled flaxseed and flaxseed oil increased plasma phospholipid n-3 fatty acids without altering glycemic control in adults with type 2 diabetes.
Thirty-four adults with type 2 diabetes were randomized to consume bakery products daily for 12 weeks containing no flax (control, n=9), milled flaxseed (32 g/d, n=13), or flaxseed oil (13 g/d, n=12; both flax groups provided 7.4 g/d alpha-linolenic acid). Both flax groups had increases in plasma phospholipid n-3 fatty acids (ALA, EPA, or DPA, but not DHA), and the flaxseed oil group had more EPA and DPA compared to the milled flaxseed group. The control group experienced a 4% weight gain compared to baseline (p < 0.05), while weight remained constant in both flax groups. All other parameters, including glycemic control, were unchanged by dietary treatment.
- Study type
- Parallel randomized controlled trial
- Who was studied
- 34 adults with type 2 diabetes (17 men, 17 women; age 52.4 +/- 1.5 years, BMI 32.4 +/- 1.0 kg/m2)
- What was measured
- Fasting HbA1c, glucose, insulin, phospholipid fatty acids, leptin, adiponectin, body weight, BMI, and waist circumference
THE PAPER
Dietary milled flaxseed and flaxseed oil improve N-3 fatty acid status and do not affect glycemic control in individuals with well-controlled type 2 diabetes.
Taylor CG, Noto AD, Stringer DM, Froese S, Malcolmson L. J Am Coll Nutr, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.